Title | Venous sinus stenting lowers the intracranial pressure in patients with idiopathic intracranial hypertension. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Patsalides A, Oliveira C, Wilcox J, Brown K, Grover K, Gobin YPierre, Dinkin MJ |
Journal | J Neurointerv Surg |
Volume | 11 |
Issue | 2 |
Pagination | 175-178 |
Date Published | 2019 Feb |
ISSN | 1759-8486 |
Keywords | Adolescent, Adult, Body Mass Index, Child, Female, Humans, Intracranial Pressure, Male, Middle Aged, Prospective Studies, Pseudotumor Cerebri, Stents, Transverse Sinuses, Venous Pressure, Young Adult |
Abstract | AIMS: We report the cerebrospinal fluid opening pressure (CSF-OP) measurements obtained before and after venous sinus stenting (VSS) in 50 patients with idiopathic intracranial hypertension. METHODS: The CSF-OP was measured with a spinal tap 3 months before and 3 months after treatment. All data were prospectively collected and included patient demographics, weight (kg), body mass index (BMI), acetazolamide daily dosage (mg), procedural details, complications, venous sinus pressures (mm Hg), trans-stenotic pressure gradient (mm Hg), transverse sinus symmetry, and type of venous sinus stenosis. RESULTS: The average pretreatment CSF-OP was 37 cm HO (range 25-77) and the average post-treatment CSF-OP was 20.2 cm HO (range 10-36), with an average reduction of 16.8 cm HO (P<0.01). The post-treatment CSF-OP was less than 25 cm HO in 40/50 patients. The average acetazolamide daily dose decreased from 950 mg to 300 mg at the time of 3-month follow-up (P<0.01). No patient required an increase in acetazolamide dose 3 months after VSS. The average weight before treatment was 95.4 kg with an average BMI of 35.41. There was an average increase in body weight of 1.1 kg at the 3-month follow-up with an average increase in BMI of 0.35 (P=0.03). CONCLUSIONS: We provide evidence that there is a significant decrease in CSF-OP in patients with idiopathic intracranial hypertension 3 months after VSS, independent of acetazolamide usage or weight loss. |
DOI | 10.1136/neurintsurg-2018-014032 |
Alternate Journal | J Neurointerv Surg |
PubMed ID | 29871989 |
PubMed Central ID | PMC6582809 |